INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 9 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,197,000 | +15.5% | 1,601,000 | 0.0% | 0.00% | – |
| Q2 2022 | $1,036,000 | -61.3% | 1,601,000 | -63.8% | 0.00% | – |
| Q1 2022 | $2,674,000 | +5.1% | 4,426,000 | 0.0% | 0.00% | – |
| Q4 2021 | $2,545,000 | -53.4% | 4,426,000 | -52.7% | 0.00% | -100.0% |
| Q3 2021 | $5,460,000 | -12.8% | 9,351,000 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $6,259,000 | +2.1% | 9,383,000 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $6,132,000 | +49.6% | 9,455,000 | +33.1% | 0.00% | 0.0% |
| Q4 2020 | $4,098,000 | -29.2% | 7,105,000 | -14.7% | 0.00% | 0.0% |
| Q3 2020 | $5,790,000 | +52.8% | 8,329,000 | +58.7% | 0.00% | 0.0% |
| Q2 2020 | $3,789,000 | +161.5% | 5,248,000 | +218.1% | 0.00% | – |
| Q1 2020 | $1,449,000 | -65.6% | 1,650,000 | -48.2% | 0.00% | -100.0% |
| Q4 2019 | $4,210,000 | +178.1% | 3,186,000 | +90.2% | 0.00% | – |
| Q3 2019 | $1,514,000 | +52.6% | 1,675,000 | +67.5% | 0.00% | – |
| Q2 2019 | $992,000 | – | 1,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,814,000 | $5,191,000 | 3.20% |
| DLD Asset Management, LP | 12,500,000 | $11,219,000 | 0.70% |
| Senvest Management, LLC | 5,000,000 | $4,345,000 | 0.51% |
| Context Capital Management, LLC | 985,000 | $863,000 | 0.49% |
| LINDEN ADVISORS LP | 30,755,000 | $26,983,000 | 0.48% |
| SSI INVESTMENT MANAGEMENT LLC | 5,896,000 | $5,014,000 | 0.44% |
| BOOTHBAY FUND MANAGEMENT, LLC | 4,386,000 | $3,812,000 | 0.32% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 16,582,000 | $14,449,000 | 0.31% |
| CSS LLC/IL | 3,825,000 | $3,410,000 | 0.27% |
| Polar Asset Management Partners Inc. | 13,000,000 | $11,372,000 | 0.23% |